AstraZeneca (LON: AZN) Lifts Full-Year Outlook After Q3 Beat, Doubles Down on US Investments
Drugmaker AstraZeneca (LON: AZN) lifted its annual sales and profit forecast for the second time this year on Tuesday, helped […]
Healthcare
US Minority Veterans Face Unequal Access to Ozempic and Wegovy, Study Finds
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk’s (NYSE: NVO) highly in-demand drugs for diabetes
US Minority Veterans Face Unequal Access to Ozempic and Wegovy, Study Finds Read More »
Healthcare
Evotec (NASDAQ: EVO) Stock Surges After Triton Acquires Nearly 10% Stake, Mulls Buyout Bid
Shares in Evotec (NASDAQ: EVO) soared 22% on Monday after private equity firm Triton confirmed a close to 10% stake
Grifols (NASDAQ: GRFS) Reaffirms 2024 Outlook as Core Earnings Rise 27% in Q3
MADRID – On Thursday, Grifols (NASDAQ: GRFS), the Spanish drugmaker, said it was on track to meet its targets for
Grifols (NASDAQ: GRFS) Reaffirms 2024 Outlook as Core Earnings Rise 27% in Q3 Read More »
Oaktree Capital Urges Indivior to Refresh Board
Oaktree Capital Management, the investment fund, has urged British drugmaker Indivior (NASDAQ: INDV) to cooperate with the fund in refreshing
Oaktree Capital Urges Indivior to Refresh Board Read More »
Healthcare
Qiagen (NYSE: QGEN) Reports Q3 Revenue Growth
On Wednesday, Qiagen (NYSE: QGEN) reported a rise in third-quarter revenue, owing to strong sales of its diagnostic devices. The
Qiagen (NYSE: QGEN) Reports Q3 Revenue Growth Read More »
Gilead Sciences (NASDAQ: GILD) Stock Jumps on Upbeat Q3 Results, Full-Year Outlook
Gilead Sciences (NASDAQ: GILD) reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%,
Gilead Sciences (NASDAQ: GILD) Stock Jumps on Upbeat Q3 Results, Full-Year Outlook Read More »
Novo Nordisk CFO Forecasts High-Teens Sales Growth for 2025
LONDON – Novo Nordisk’s (NYSE: NVO) sales growth next year could be in the high teens in percentage terms, Chief
Novo Nordisk CFO Forecasts High-Teens Sales Growth for 2025 Read More »
Teva Pharm CEO Says Will Work Productively with Trump Administration
JERUSALEM – Teva Pharmaceutical Industries (NYSE: TEVA) expects to work productively with the incoming Trump administration in the United States,
Teva Pharm CEO Says Will Work Productively with Trump Administration Read More »
